(Q33900416)

29 July 2017

1 reference

title

Strategies for combining chemotherapy and biotherapy in melanoma (English)

1 reference

29 July 2017

Buzaid AC

1

1 reference

29 July 2017

publication date

1 March 2000

1 reference

29 July 2017

1 reference

29 July 2017

volume

7

1 reference

29 July 2017

issue

2

1 reference

29 July 2017

page(s)

185-197

1 reference

29 July 2017

cites work

Cancer statistics, 1999.

1 reference

https://api.crossref.org/works/10.1177%2F107327480000700214

Sequential chemoimmunotherapy in the treatment of metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480000700214

Combination of chemotherapy with interleukin-2 and interferon alfa for the treatment of metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480000700214

Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alfa, and interleukin-2 for patients with metastatic melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480000700214

Treatment of metastatic melanoma with combined chemotherapy containing cisplatin, vinblastine and dacarbazine (CVD) and biotherapy using interleukin-2 and interferon-alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480000700214

Chemoimmunotherapy of advanced malignant melanoma: sequential administration of subcutaneous interleukin-2 and interferon-α after intravenous dacarbazine and carboplatin or intravenous dacarbazine, cisplatin, carmustine and tamoxifen

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480000700214

Randomized phase II trial of BCDT [carmustine (BCNU), cisplatin, dacarbazine (DTIC) and tamoxifen] with or without interferon alpha (IFN-alpha) and interleukin (IL-2) in patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480000700214

Activation of human NK cells and monocytes with cisplatin in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480000700214

Enhanced susceptibility of cis-diamminedichloroplatinum-treated K562 cells to lysis by peripheral blood lymphocytes and lymphokine activated killer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480000700214

The anticancer drug, cisplatin, increases the naturally occurring cell-mediated lysis of tumor cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480000700214

Inhibition of DNA repair and sensitization of cisplatin in human ovarian carcinoma cells by interleukin-1 alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480000700214

Rationale for using TNF alpha and chemotherapy in regional therapy of melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480000700214

The L-arginine-nitric oxide pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480000700214

Flavone acetic acid (FAA) with recombinant interleukin-2 (TIL-2) in advanced malignant melanoma. II: Induction of nitric oxide production

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480000700214

Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480000700214

10.1177/107327480000700214

21 January 2018

Identifiers

DOI

0 references

1 reference